Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna
07:53am, Saturday, 05'th Oct 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options NEW YORK
MRNA Deadline: MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit
03:10pm, Friday, 04'th Oct 2024
NEW YORK , Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024,
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Moderna, Inc.
11:00am, Friday, 04'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "th
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you su
Global mRNA Cancer Vaccine Clinical Trial FDA Approval Market Size Future Opportunity Companies Insight
06:55am, Friday, 04'th Oct 2024
First commercial Approval Of mRNA Cancer Vaccine Is Expected In Near Future Says Kuick Research First commercial Approval Of mRNA Cancer Vaccine Is Expected In Near Future Says Kuick Research
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 2
Moderna Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Reach Out To The Schall Law Firm
11:00am, Thursday, 03'rd Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "th
NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) and certain officers. The c
October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA
12:54pm, Wednesday, 02'nd Oct 2024
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA).
MRNA LAWSUIT ALERT: Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
11:15am, Wednesday, 02'nd Oct 2024
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, foll
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Moderna, Inc.
11:00am, Wednesday, 02'nd Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "th
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna, Inc. Lawsuit - MRNA
07:15am, Wednesday, 02'nd Oct 2024
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, foll
MRNA Investors Have Opportunity to Lead Moderna, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
07:00am, Wednesday, 02'nd Oct 2024
NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna,
Abbas Hussain Joins Moderna's Board of Directors
07:00am, Wednesday, 02'nd Oct 2024
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma As former Global President of GSK, Pharmaceuticals and V
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
04:46am, Wednesday, 02'nd Oct 2024
Could rebounds be in store for these beaten-down stocks?
